USE OF IMMUNOMODULATORS IN THE TREATMENT OF CELIAC DISEASE: WHAT IS KNOWN SO FAR?

• DOI: 10.22533/at.ed.1593252303043

• Palavras-chave: Celiac disease; Immunomodulators; Monoclonal Immunomodulators

• Keywords: Celiac disease; Immunomodulators; Monoclonal Immunomodulators

• Abstract:

  Celiac disease is an autoimmune disease of the small intestine, triggered by the ingestion of gluten in genetically predisposed individuals. Conventional treatment includes a gluten-free diet and, in some cases, immunomodulators to control the autoimmune response.

  Corticosteroids are often used as immunomodulators to treat refractory celiac disease, but their long-term use is limited due to systemic side effects. Immunosuppressants, such as azathioprine and tacrolimus, are also used to treat refractory celiac disease, with possible side effects including suppression of the immune system. Biological immunomodulators, such as the monoclonal antibody specific for IL-15, can be used to modulate the celiac disease-specific immune response, with potential efficacy and less toxicity. Oral tolerance molecule is another immunomodulator under study for the treatment of celiac disease, aiming to induce immune tolerance to gluten.

  Although immunomodulators offer a promising option in the treatment of refractory celiac disease, it is important to remember that the use of these agents must be under proper medical supervision and careful monitoring for possible side effects. In addition, the gluten-free diet is still the most effective and essential treatment for the control of celiac disease.